Featured Research

from universities, journals, and other organizations

New Clue To Diagnosis And Treatment Of Malignant Melanoma

Date:
January 15, 2001
Source:
Cold Spring Harbor Laboratory
Summary:
Malignant melanoma is an aggressive, deadly cancer that does not respond to conventional chemotherapy. Other aggressive, chemoresistant cancers — and approximately half of all cancers — are characterized by mutations in the p53 tumor suppressor gene. Malignant melanomas, however, do not typically display mutations in the p53 gene. To explore alternative explanations for the origins and properties of malignant melanoma, and to identify potential targets and strategies for therapy, Scott Lowe and his colleagues at Cold Spring Harbor Laboratory have examined the status of other genes known to function downstream of p53 in a pathway leading to "apoptosis" or "programmed cell death."

Cold Spring Harbor, NY -- Malignant melanoma is an aggressive, deadly cancer that does not respond to conventional chemotherapy. Other aggressive, chemoresistant cancers — and approximately half of all cancers — are characterized by mutations in the p53 tumor suppressor gene. Malignant melanomas, however, do not typically display mutations in the p53 gene.

To explore alternative explanations for the origins and properties of malignant melanoma, and to identify potential targets and strategies for therapy, Scott Lowe and his colleagues at Cold Spring Harbor Laboratory have examined the status of other genes known to function downstream of p53 in a pathway leading to "apoptosis" or "programmed cell death." When intact, this pathway rids the body of abnormal, pre-cancerous cells by triggering a cellular self-destruct mechanism. When this pathway is disrupted (by the loss of p53 function, for example), pre-cancerous cells survive and proliferate resulting in cancer (see figure).

In a study to be published tomorrow in Nature, Lowe and his colleagues report that malignant melanomas often lose a key trigger of programmed cell death — a protein called Apaf-1 (apoptosis activation factor-1). The researchers also discovered that the loss of Apaf-1 in melanoma cells is associated with resistance to the chemotherapy drug adriamycin. Most significantly, the study shows that restoring Apaf-1 in melanoma cells rescues the ability of these tumor cells to kill themselves in response to adriamycin.

"The loss of Apaf-1 in malignant melanoma is a prime explanation for both the extreme chemoresistance and the apparent lack of p53 defects in such cancers," says Lowe.

The study is significant because it demonstrates that accurate diagnosis and treatment of malignant melanoma, and perhaps other cancers, should include an assessment of the status of Apaf-1.

Maria Soengas of Cold Spring Harbor Laboratory was the principal author of the study. The principal collaborators in the study were William L. Gerald and Carlos Cordon-Cardo of Memorial Sloan-Kettering Cancer Center.

An intriguing aspect of the study relates to the mechanisms that cause the loss of Apaf-1 in melanomas. The researchers were not surprised to find that one of the two copies of the Apaf-1 gene was deleted in many of the melanomas they examined (a well-known phenomenon called "loss of heterozygosity"). However, the other Apaf-1 gene copy in these cells was present and apparently normal in terms of its DNA sequence. Interestingly, Lowe and his colleagues found that complete loss of Apaf-1 was due to "transcriptional silencing" of the remaining, normal copy of the Apaf-1 gene in melanomas. Transcriptional silencing, or the suppression of gene expression due to higher order chromatin structure, is emerging as a principle mechanism whereby Apaf-1 and other tumor suppressor genes can be inactivated, resulting in cancer when other copies of such genes are lost, mutated, or similarly silenced.

Scott Lowe is a Professor at Cold Spring Harbor Laboratory and Deputy Director of the Cold Spring Harbor Laboratory Cancer Center. Other scientists from Memorial Sloan-Kettering Cancer Center (Paolo Capodieci, David Polsky, Jaume Mora), Johns Hopkins University and Oncology Center (Manel Esteller, James G. Herman), and Cold Spring Harbor Laboratory (Ximena Opitz-Araya, W. Richard McCombie, Yuri A. Lazebnik) contributed to the study.


Story Source:

The above story is based on materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "New Clue To Diagnosis And Treatment Of Malignant Melanoma." ScienceDaily. ScienceDaily, 15 January 2001. <www.sciencedaily.com/releases/2001/01/010111075020.htm>.
Cold Spring Harbor Laboratory. (2001, January 15). New Clue To Diagnosis And Treatment Of Malignant Melanoma. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/01/010111075020.htm
Cold Spring Harbor Laboratory. "New Clue To Diagnosis And Treatment Of Malignant Melanoma." ScienceDaily. www.sciencedaily.com/releases/2001/01/010111075020.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins